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Albumin denaturationAbstract A series of schiff base derivatives of 4-aminophenazone (4APZ-1,5-dimethyl-2-phenyl-
1,2-dihydro-3H-pyrazol-3-one) with different aldehydes were synthesized. The synthetic compounds
were screened for their anti-inﬂammatory, analgesic and antipyretic activities. The characterization
of synthesized compounds was carried out by 1H NMR, 13C NMR and MS. Carrageenan-induced
paw oedema (CIPO) and histamine induced paw oedema (HIPO) methods were used to determine
the anti-inﬂammatory activity of commercial sample of 4APZ and its synthesized schiff bases in
mice. The anti-inﬂammatory activity was in the order of 4APZAB> 4APZBB > 4APZC-
B > 4APZVn and all the test compounds exhibited considerable dose dependent inhibition of
the paw oedema. The effect of the compounds on membrane stabilization was also determined
which showed that compounds 4APZ (120 and 240 mg/kg doses), 4APZAB (160 mg/kg) and
4APZVn (600 mg/kg) produced highly signiﬁcant inhibition (P< 0.001) of hypotonicity-induced
haemolysis. Further, it was also observed that 4APZ (120 and 240 mg/kg doses), 4APZBB
(500 mg/kg) and APZCB (150, 300 and 600 mg/kg dose) produced highly signiﬁcant inhibition
(P< 0.001) of albumin denaturation; a consistent dose dependent anti-inﬂammatory effect of test
compounds as compared to the standard drug. Analgesic activity of the compounds was investi-
gated by formalin-induced paw licking (FIPL) and acetic acid-induced writhing (AIW) methods
in mice. It was observed that 4APZ (240 mg/kg), 4APZAB (160 mg/kg), 4APZBB (500 mg/kg),
4APZCB (600 mg/kg) and 4APZVn (600 mg/kg) showed analgesic effect with highly signiﬁcant
(P< 0.001) reduction of paw licking and writhing activity in the treated mice. The order of
S360 S. Murtaza et al.analgesic effect of the compounds was 4APZAB > 4APZBB > 4APZVn > 4APZCB. Moreover,
phenobarbitone-induced sleeping time (PIST) in mice was also studied but only 600 mg/kg of
4APZVn signiﬁcantly increased the duration of induced sleep which also suggested its sedative
property. Brewer’s yeast was used to induce fever in rabbits and analysed the compounds for their
antipyretic activity. Different doses of 4APZ for different time durations (240 mg/kg-after 1 h, 120
and 240 mg/kg doses-after 2 h) produced highly signiﬁcant (P< 0.001) inhibition of hyperpyrexia.
Other compounds showed good antipyretic activity after 2, 3 and 4 h.
ª 2014 King Saud University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Due to side effects of existing available anti-inﬂammatory,
analgesic and antipyretic medicines that have been creating
serious problems in their clinical applications, it is crucial to
synthesize and develop novel and more potent anti-inﬂamma-
tory, analgesic and antipyretic drugs with no or fewer side
effects. Therefore, in the present study a known active com-
pound ‘‘4-aminophenazone’’ was modiﬁed into its schiff bases
with four different benzaldehydes. The biological applications
of schiff bases like antibacterial, antifungal, antiviral and
anticancer agents are well known particularly due to the
azomethine group (–CH‚N–) [30,6]. 4-Aminophenazone has
pyrazol-3-one fragment (another important moiety) which also
is found in several biologically active molecules that have
important roles in the animal as well as plant kingdoms.
Compounds bearing pyrazol-3-one possess antibacterial [53],
anti-inﬂammatory [4], antihypertensive [20], antifungal [42],
anti-HIV [9], antitumor [40] and anticonvulsant activities
[41]. Pyrazol-3-one nucleus having azomethine linkage has
engrossed much attention in the ﬁeld of pharmacy due to their
expected efﬁciency. Considering pyrazol-3-one as a possible
pharmacophore in various pharmacologically active agents,
it was decided to synthesize schiff bases of pyrazol-3-one and
investigate their anti-inﬂammatory, analgesic and antipyretic
activities.
Inﬂammation has acquired the attention of global research
due to its implication in both human and animal diseases.
Inﬂammatory abnormalities are considered as a giant group
of disorders that trigger a huge variety of human diseases.
Inﬂammation is a crucial aspect of host response that escorts
to infection, and is requisite to keep healthy condition against
microbial infections. However, excessive inﬂammation may
contribute to acute or chronic human diseases. Acne vulgaris,
asthma, glomerulonephritis, hypersensitivities, coeliac disease,
chronic prostatitis, inﬂammatory bowel diseases, rheumatoid
arthritis, sarcoidosis, pelvic inﬂammatory disease, reperfusion
injury, transplant rejection, autoimmune diseases, interstitial
cystitis and vasculitis [43,8] are some examples of disorders
associated with inﬂammation. Non-steroidal anti-inﬂamma-
tory drugs (NSAIDs) were the ﬁrst group that was used to
treat inﬂammatory diseases. These drugs lessen inﬂammation
and assist to relieve pain, however, seldom entirely eradicate
signs of active arthritis [26]. A wide variety of NSAIDs is avail-
able, many of which cause inhibition of cyclooxygenase
(COX). The enzyme is responsible for the conversion of arachi-
donic acid into prostaglandins [51].
Commonly used anti-inﬂammatory drugs such as NSAIDs
and analgesic agents are associated with some adverse effectssuch as myocardial infarction [21], congestive heart failure
[37], nausea/vomiting, dyspepsia, gastric ulceration/bleeding,
diarrhoea [52] hypertension and salt and ﬂuid retention. The
NSAIDs may also cause renal failure when used in combina-
tion with some diuretic and ACE inhibitors (triple whammy
effect) [50], nephrotic syndrome, interstitial nephritis, acute
tubular necrosis and acute renal failure. NSAIDs may also
be causing analgesic nephropathy when used in combination
with phenacetin and/or paracetamol [10], photosensitivity
[28], premature birth [34], hepatotoxicity [56], raised liver
enzymes, hyperkalaemia, bronchospasm, rash and allergy,
headache, dizziness, confusion [46].
NSAIDs have been extensively used for the treatment of
minor pain and for the management of oedema and tissue
damage resulting from inﬂammatory joint disease (arthritis).
Unlike NSAIDs which cure both inﬂammation and pain, anal-
gesics purely target the pain. This property makes it safer for
those who have allergic or stomach problems with NSAIDs.
Many analgesic drugs have antipyretic activity as well and
hence have effectiveness in the treatment of fever. Most of
these drugs show their therapeutic actions by inhibition of
prostaglandin biosynthesis [32].
2. Experimental
2.1. Materials
4-Aminophenazone (4-amino-1,5-dimethyl-2-phenyl-1,2-dihy-
dro-3H-pyrazol-3-one, 4APZ) and 4-dimethylaminobenzalde-
hyde were purchased from BDH, 4-chlorobenzaldehyde and
4-bromobenzaldehyde from ACROS, and vanillin from Alfa.
Piroxicam (Hovid, Malaysia). Acetylsalicylic acid (Reckit &
Colman, Karachi), Phenobarbitone (Amros Pharmaceuticals,
Karachi), Formalin (MERCK, Darmstadt, Germany), Acetic
acid (BDH Laboratories, Poole, England), Dried yeast (Sigma
Chemical Company, St. Louis, MO, USA), Gum Tragacanth
(MERCK, Darmstadt, Germany), Carboxymethylcellulose
(MERCK, Darmstadt Germany), Carrageenan (Sigma Chem-
ical Company, St. Louis, MO, USA). Histamine (BDH Labo-
ratories, Poole, England). Albumin kit (Randox Laboratories,
United Kingdom). NMR spectra (300 MHz, in CDCl3);
Bruker AM-300; d(H) in ppm. Using CDCl3 as an internal ref-
erence [1H (CDCl3) = 7.25 and
13C (CDCl3) = 77]. ESI-MS:
solvent; MeOH, spray voltage 1.4 kV.
2.2. General procedure for the preparation of schiff bases
Schiff bases of 4-aminophenazone (4APZ) were prepared by
standard procedure (Scheme 1). The solutions of 4APZ and
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Scheme 1 Synthesis of schiff bases of 4-aminophenazone.
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trile. Solutions were mixed and the obtained mixtures were
reﬂuxed for 3 h at 60 C. Schiff bases were precipitated out
on cooling to room temperature and then ﬁltered off. The pre-
cipitates were washed several times with acetonitrile and
recrystallized by dichloromethane.
2.3. Biological studies
2.3.1. Animals used
Adult Swiss albino mice of either sex, weighing 20–30 g and
healthy adult rabbits of a local strain (Oryctolagus cuniculus);
weighing 1–1.5 kg were used in these investigations. Mice were
bred in Department of Pharmacy, University of Sargodha,
Sargodha, Pakistan and housed in stainless cages under
controlled room temperature (25 ± 10 C; relative humidity
60–70%). Rabbits were kept at animal house of the said
department. Food and water were provided ad libitum.
Guidelines provided by ethics committee of NIH were used
to handle the animals. Seventeen groups of animal (mice and
rabbits) were arranged with six animals in each group. Mice
were used for the anti-inﬂammatory and analgesic studies
while rabbits were used to determine the antipyretic activity
of the compounds.
2.3.2. Drug administration
2.3.2.1. Oral administration. The drugs were administered
orally by using oral gavages. 1 cc B.D syringe needle was
removed and Ryle tube #4, attached to needle No. 17 was ﬁxed
at the place of original needle. Animal was maintained in
standing position and the gavage was then passed from the side
of mouth, subsequently the tube was entered to the oesopha-
gus and stomach. Thus the solution was directly injected to
the stomach by pressing the nozzle of syringe.
2.3.2.2. Intraperitoneal administration. The drug was intraperi-
toneally administered to animal as the animal was manually
controlled with right hind limb immobilized with head and
body slanted downward. A 25 guage needle was promptly
inserted into the peritoneal cavity in the caudal right abdomi-
nal quadrant through the skin and abdominal wall. Injection
into the caecum or the stomach on the left side was thus
avoided. The needle tip was then lifted slightly and material
was released by pressing plunger of syringe.
2.3.3. Subcutaneous administration
The skin of rabbit was lifted with ﬁngers controlling it in a nor-
mal manner; a triangle was formed when traction was appliedto the rabbit’s skin, the injection needle was inserted between
the folds of skin into the base of the triangle. Disinfected the
injection site and inserted the needle into the subcutaneous
tissue.
2.3.4. Preparation of solutions/suspensions of various drugs
Suspension of gum tragacanth 1% (w/v) was prepared by
adding 1 g of gum tragacanth in 100 ml of distilled water. Car-
rageenan suspension 1% (w/v) was prepared by suspending 1 g
of carrageenan in 100 ml of normal saline. Histamine solution
was prepared by dissolving 1 g of histamine in 100 ml of nor-
mal saline. Formalin solution (2.5% (v/v)) was prepared by
dissolving 37% formalin (3.37 ml) in 50 ml of distilled water.
Acetic acid solution (0.6% (v/v)) was prepared by dissolving
acetic acid (0.6 ml) in 100 ml of distilled water. Brewer’s yeast
suspension (15% (w/v)) was prepared by suspending brewer’s
yeast (15 g) in 100 ml of normal saline. Suspensions of all test
compounds were prepared by suspending the powdered com-
pounds in 1% gum tragacanth for mice and in 1% suspension
of CMC for rabbits. On the basis of the pilot study, the test
doses were selected for the study of pharmacological effects.
The group name, compound administered and the dose
amount are listed in Table 1.
2.4. Experimental procedures
2.4.1. Anti-inﬂammatory studies through carrageenan-induced
paw oedema in mice
Anti-inﬂammatory effect of 4APZ and its derivatives (1–4) was
evaluated by CIPO in mice by following the method reported
by Nawafor and Okwuasaba [31]. Albino mice were divided
into 17 groups of six mice each. The mice were fasted for
24 h before the experiment with free access to water. The con-
trol group was labelled as group ‘‘G1’’ and was given gum
tragacanth suspension 1 ml/kg (p.o.) [1]. Group 2 was treated
with the standard drug, piroxicam 5 mg/kg [24]. Likewise three
different doses of each ﬁve test compounds suspended in gum
tragacanth have been administered orally to all other groups of
animals by a feeding tube. The inﬂammation of the hind paw
was produced 1 h after the treatment by injecting 0.1 ml freshly
prepared carrageenan suspension (1%) in normal saline [23] on
the plantar surface of the left hind paw of mice and the site of
injection was marked.
Anterio-posterior diameter of the paw was measured by
using vernier caliper immediately after the carrageenan
injection and at 1, 2 and 3 h intervals after the carrageenan
injection at the marked site. The difference between the basal
value and that measured at different time intervals was noted
Table 1 Animal group name, compound administered and the dose amount.
Group name G2 G3 G4 G5 G6 G7 G8 G9
Compound Piroxicam 4APZ 4APZ 4APZ 4APZAB 4APZAB 4APZAB 4ABZBB
Dose 5 mg/kg 60 mg/kg 120 mg/kg 240 mg/kg 40 mg/kg 80 mg/kg 160 mg/kg 125 mg/kg
Group name G10 G11 G12 G13 G14 G15 G16 G17
Compound 4ABZBB 4ABZBB 4APZCB 4APZCB 4APZCB 4APZVn 4APZVn 4APZVn
Dose 250 mg/kg 500 mg/kg 150 mg/kg 300 mg/kg 600 mg/kg 150 mg/kg 300 mg/kg 600 mg/kg
S362 S. Murtaza et al.in millimetres. This difference was recorded as inﬂammation
developed after carrageenan injection [19]. The left hind paw
oedema inhibition at different doses of test compounds and
standard drug was calculated by comparison with untreated
control mice by the following formula:
Percentage inhibition of paw oedema
¼ ðVtVoÞcontrolðVtVoÞtreated
n o
=ðVtVoÞcontrol
h i
100
where Vt is the rat paw volume at time ‘t’, Vo is the initial rat
paw volume (basal value), (Vt  Vo)control is oedema produced
in the control group and (Vt  Vo)treated is oedema produced
in the treatment group.
2.4.2. Anti-inﬂammatory studies through HIPO in mice
Anti-inﬂammatory activity of the tested compounds was eval-
uated by HIPO in mice according to the standard procedure by
Suralkar [48]. Albino mice were divided into 17 groups of six
mice each. The mice have been fasted for 24 h before the exper-
iment with free access to water.
The control group (G1) was treated with gum tragacanth
suspension 1 ml/kg (p.o.). Group 2 was treated with piroxi-
cam 5 mg/kg. In the same manner three different doses of
each ﬁve test compounds suspended in gum tragacanth have
been administered orally to all other groups of animals by a
feeding tube. After 1 h of treatment the inﬂammation of the
hind paw was produced by injecting 0.1 ml freshly prepared
histamine solution (1%) on the plantar surface of the left
hind paw of mice and the site of injection was marked.
Anterio-posterior diameter of the paw was measured by
using vernier caliper immediately after the histamine injec-
tion and at 1, 2 and 3 h intervals after the histamine injec-
tion at the marked site. The difference between the basal
value and that measured at different time intervals was
noted in millimetres. This difference was recorded as amount
of oedema.
Percentage inhibition of paw oedema ¼ ½ðVc VtÞ=Vc  100
where Vt and Vc represent oedema volume in the drug treated
and control groups, respectively.
2.4.3. Effect of the synthetic compounds on membrane
stabilization
2.4.3.1. Preparation of erythrocyte suspension. Membrane sta-
bilization activity was carried out according to the method
described by Shinde et al. [44] and Olajide et al. [33] with some
modiﬁcations. Blood sample (2 ml) was collected from normal
rabbits. The blood was centrifuged and the supernatant was
carefully removed with a sterile pipette. The packed cells were
re-suspended in an equal volume of isotonic saline and centri-
fuged again. The process was repeated four times to make thesupernatants clear. A 10% red blood cell (RBC) suspension
was then prepared with normal saline and kept at 4 C before
use. The reaction mixture (4.5 ml) was prepared by taking 2 ml
of hypotonic saline and 2.5 ml of RBCs suspension (volume of
blood measured and reconstituted as 40% (v/v) suspension in
10 mM isotonic buffer solution which contained (g/l) of
NaH2PO4 (0.2), Na2HPO4 (1.15) and NaCl (9.0).
2.4.4. Hypotonicity-induced haemolysis
The hypotonic solution containing different doses of the tested
compounds in gum tragacanth was added to test tubes.
Control tube contained 1 ml/kg of gum tragacanth or piroxi-
cam 5 mg/kg. 0.5 ml of 10% HRBC and the control solution
were added to each tube. Each tube was gently mixed and
the mixtures were incubated at 56 C for 30 min. The tubes
were cooled under running water for 20 min, and mixtures
were centrifuged. The absorbance of supernatants was read
at 540 nm wavelength using spectrophotometer. The percent-
age membrane-stabilizing activity was determined by using
following relation.
Percentage inhibition of haemolysis ¼ ð1A2=A1Þ  100
where A1 = Absorption of the control solution and A2 =
Absorption of test sample solution.
2.4.5. Determination of inhibition of albumin denaturation by
test compounds
Randox kit method was used to determine albumin level. The
procedure involved the collection of blood sample from three
normal rabbits. The serum of these blood samples was
separated through centrifugation. Randox kit method was
then applied and albumin level was measured in g/dl by using
Biolyzer.
2.4.6. Analgesic studies through Formalin-induced paw licking
(FIPL) in mice
Nawafor and Okwuasaba [31] method was used to assess the
analgesic effect of the compounds against formalin-induced
paw licking in mice. Adult albino mice of weight 25–30 g of
either sex were randomized into 17 groups for the experiments.
Each group contains six mice and they were fasted for 24 h and
were pretreated with different amounts of test compounds and
piroxicam (5 mg/kg) orally before being challenged with for-
malin. 20 ll of 2.5% formalin solution (0.9% of formaldehyde)
was injected subcutaneously under the surface of the right hind
paw of each mouse and the responses were observed for
30 min. The group of control mice was given gum tragacanth
(1 ml/kg) orally. The duration (time in seconds) spent in lick-
ing and biting the injected paw was noted that is the indication
of pain. The ﬁrst phase of the analgesic activity normally
peaked at 5 min after formalin injection representing the neu-
Synthesis and biological evaluation of schiff bases of 4-aminophenazone S363rogenic response and the second phase 15–30 min after forma-
lin injection representing inﬂammatory pain response.
2.4.7. Analgesic studies through acetic acid-induced writhing
(AIW) test in mice
Koster et al. [22], method was employed to determine the
analgesic action of test compounds. One hundred and two
mice were separated into 17 groups of six mice each. The ani-
mals were treated with a dose of 1 ml/kg of gum tragacanth,
different amounts of compounds suspended in gum traga-
canth or piroxicam (5 mg/kg) orally. Thirty minutes later,
animals in all groups were treated with 10 ml/kg of 0.6% v/
v acetic acid intraperitoneally. The numbers of writhes were
counted 5 min after acetic acid injection for a period of
10 min.
Percentage inhibition of writhing was calculated using the
following formula:Percentage inhibition ¼ Mean number of writhing ðcontrolÞ Mean number of writhing ðtestÞ
Mean number of writhing ðcontrolÞ  1002.4.8. Phenobarbitone induced sleeping time (PIST) test in mice
Williamson et al. [57] method of Phenobarbitone induced
sleeping time was employed on Albino mice (17 groups of 6
mice each). Group I was kept as control and given gum trag-
acanth suspension 1 ml/kg (p.o.) [1]. Piroxicam (5 mg/kg)
was given to Group II [24]. In a similar way, all other groups
of animals were given three different doses of each ﬁve test
compounds suspended in gum tragacanth orally. After
30 min phenobarbitone sodium (25 mg/kg) body weight of ani-
mal was administered intraperitoneally to all the groups. The
onset of sleep and total sleeping time were recorded for control
as well as for treated groups.
2.4.9. Antipyretic studies through yeast induced hyper pyrexia
(YIHP) in rabbits
In this study adult healthy rabbits (weight 1–1.5 kg) were cho-
sen and randomly divided into 17 groups of six rabbits each.
S.C injection of brewer’s yeast suspension (2 ml) in saline solu-
tion was used to induce Pyrexia. Carboxymethylcellulose
(CMC) suspension 2 ml/kg (p.o.) was administered to the ani-
mals of Group 1 (control group) while Group 2 animals were
treated with acetylsalicylic acid (100 mg/kg) a standard drug
[17], after 12 h of yeast injection. In a same manner, other
groups were orally given three different doses of each test com-
pound suspended in 1% CMC. Rectal temperature was noted
at 1 h interval up to 4 h [36].
2.4.10. Acute toxicity and behavioural pattern studies
Toxic effects of the tested compounds were preliminarily
screened by keeping the treated animals (mice and rabbits)
under keen observation for 12 h daily for the following week.
The symptoms including awareness, CNS, mood, excitation,
muscle tone, posture, body weight, reﬂexes food consumption,
motor activity and motor in coordination were recorded for7 days. During the next 2 weeks, any mortality occurred was
also recorded [25].
2.5. Statistical analysis of numerical data by using Student’s ‘‘t’’
test
The observed outcome of the analysis was expressed as mean-
s ± SEM and the results were compared with the control
group. Student’s ‘t’ test was employed to evaluate the results.
Value P< 0.05 was considered as statistically signiﬁcant [47].
3. Results
3.1. Chemistry
In the present work, 4-aminophenazone (1,5-dimethyl-2-phe-
nyl-1,2-dihydro-3H-pyrazol-3-one) was derivatized into itsschiff bases 1–4 by the reaction of different substituted benzal-
dehydes with 4-aminophenazone according to Scheme 1. The
synthesized compounds were characterized structurally with
the help of 1H NMR, 13C NMR and MS spectrometry. The
1H NMR spectra were recorded in CDCl3 at 300 MHz. The
structural assignments of the synthesized compounds are given
below. These spectra of schiff bases (1–4) showed peaks for
methyl, aromatic and azomethine (–N‚CH–) protons. The
presence of sharp singlet at d 9.63–9.73 in the 1H NMR spectra
is in good agreement with the reported values [49] and d 123.9–
126.7 ppm in 13C NMR spectra of the schiff bases (1–4) con-
ﬁrmed the presence of azomethine (–CH‚N–) group. The
mass spectrum was found to have a fragment as (M+Na,
80–100%).
3.1.1. 4-({[4-(Dimethylamino)phenyl]methylidene}amino)-1,5-
dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one (4APZAB)
Yield: 86%, m.p. 224 ± 1 C, 1H NMR (300 MHz, CDCl3): d
(ppm) 2.49 (3H, s, CH3), 3.01 (6H, s, 2CH3), 3.21 (3H, s, CH3),
6.70 (2H, d, J= 8.25, 2CH) 7.21–7.35 (2H, m, 2CH), 7.38–
7.51 (3H, m, 3CH), 7.78 (2H, d, J= 8.25, 2CH) 9.65 (1H, s,
CH), 13C NMR (CDCl3, 300 MHz): d (ppm) 9.8 (CH3), 35.8
(CH3), 39.9 (2CH3), 111.5 (2CH), 119.3 (C), 123.9 (2CH),
125.9 (C), 126.1 (CH), 128.8 (2CH), 129.1 (2CH), 134.7 (C),
150.7 (C), 151.3 (C), 157.6 (C‚O), 161.2 (CH); MS (ES+):
m/z (%) = 357.11 (99) [M+Na]+.
3.1.2. 4-{[(4-Bromophenyl)methylidene]amino}-1,5-dimethyl-
2-phenyl-1,2-dihydro-3H-pyrazol-3-one (4APZBB)
Yield: 87%, m.p. 258 ± 1 C, 1H NMR (300 MHz, CDCl3): d
(ppm) 2.48 (3H, s, CH3), 3.18 (3H, s, N–CH3), 7.21–7.80 (9H,
m, 9CH), 9.65 (1H, s, CH) 13C NMR (CDCl3, 300 MHz): d
(ppm) 9.8 (CH3), 35.8 (CH3), 119 (C), 123.9 (CH), 124.2
(2CH), 126.6 (C), 128.7 (2CH), 128.9 (2CH), 131.4 (2CH),
S364 S. Murtaza et al.134.4 (C), 136.6 (C),152.5 (C), 155.2 (C‚O), 160.7 (CH); MS
(ES+): m/z (%) = 393.98 (99) [M+Na]+.
3.1.3. 4-{[(4-Chlorophenyl)methylidene]amino}-1,5-dimethyl-
2-phenyl-1,2-dihydro-3H-pyrazol-3-one (4APZCB)
Yield: 94%, m.p. 255 ± 1 C, 1H NMR (300 MHz, CDCl3): d
(ppm) 2.49 (3H, s, CH3), 3.18 (3H, s, CH3), 7.21–7.55 (7H, m,
7CH), 7.91 (2H, d, J= 4.5, 2CH), 9.73 (1H, s, CH); 13C NMR
(CDCl3, 300 MHz): d (ppm) 9.8 (CH3), 35.6 (CH3), 118 (C),
124.1 (2CH), 126.7 (CH), 128.3 (2CH), 128.4 (2CH), 128.9
(2CH), 134.3 (CH), 135.5 (C), 136.1 (C),151.8 (C), 155.5
(C‚O), 160.8 (CH); MS (ES+): m/z (%) = 348.79 (100)
[M+Na]+.
3.1.4. 4-{[(4-Hydroxy-3-methoxyphenyl)methylidene]amino}-
1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one
(4APZVn)
Yield: 88%, m.p. 221 ± 1 C, 1H NMR (300 MHz, CDCl3): d
(ppm) 2.47 (3H, s, CH3), 3.16 (3H, s, CH3), 3.95 (3H, s, CH3),
6.45 (1H, m, OH), 6.91 (2H, d, J= 4.5 Hz, 2CH) 7.21–7.56
(6H, m, 6CH), 9.63 (1H, s, CH), 13CNMR (CDCl3,
300 MHz): d (ppm) 9.9 (CH3), 35.4 (CH3), 55.2 (CH3), 108.2
(C), 114.1 (CH), 118.8 (CH), 122.7 (CH), 124.1 (2CH), 126.3
(C), 128.9 (2CH), 130.6 (C), 134.7 (CH), 146.4 (C), 147.8
(C), 151.2 (C), 157.4 (C‚O), 160.8 (CH); MS (ES+): m/z
(%) = 360.07 (100) [M+Na]+.
3.2. Anti-inﬂammatory action
3.2.1. By carrageenan-induced paw oedema method
Anti-inﬂammatory activity of various compoundswas observed
in mice (17 groups) after 1, 2 and 3 h of being injected with car-
rageenan injection. In the control group, mean oedema was
0.81 mm, 1.79 mm and 2.59 mm after 1, 2 and 2 h, respectively.
The anti-inﬂammatory activity of each animal was compared
with mean percentage inhibition of paw oedema (MPIPO) in
all groups. Group 2 (treated with piroxicam 5 mg/kg (p.o.))
exhibited highly signiﬁcant inhibition (SI) of paw oedema
(P< 0.001) and MPIPO observed was 85.77%, 88.29% and
89.80% after 1, 2 and 3 h, respectively. In the tested compounds
(1–4) with different doses, the groups G5, G7, G8 andG11 after
1, 2 and 3 h, the groups G3, G4, G10 and G14 after 2 and 3 h
while G6 and G13 exhibited highly SI of paw oedema
(P< 0.001) only after 3 h, see Table 2. G7 and G8 have been
treated with 4APZAB (4-({[4-(dimethylamino)phenyl]methy-
lidene}amino)-1,5-dimethyl-2-phenyl-1,2-dihy-dro-3H-pyrazol-
3-one) with doses 80 mg/kg and 160 mg/kg while G11 was
treated with 4APZBB (4-{[(4-bromophenyl)methylidene]
amino}-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-py-razol-3-one)Table 2 Signiﬁcance of the anti-inﬂammatory effects of the compou
after one, two and three hours.
Time Group
G2 G3 G4 G5 G6 G7 G8 G9
1 h ** * * ** * ** ** –
2 h ** ** ** ** * ** ** *
3 h ** ** ** ** ** ** ** *
* Signiﬁcant inhibition (P< 0.05).
** Highly signiﬁcant inhibition (P< 0.001).at 500 mg/kg. The other groups showed signiﬁcant or insigniﬁ-
cant inhibitionof pawoedema.Thedetails of the results are sum-
marized in Fig. 1.
3.2.2. By histamine-induced paw oedema method
Histamine induced method was also used to determine the anti-
inﬂammatory activity of compounds in mice (17 groups) after
1, 2 and 3 h of being injected with histamine injection. In the
control group (G1), mean oedema was 0.75 mm, 1.80 mm
and 2.56 mm after 1, 2 and 3 h, respectively. The anti-inﬂam-
matory activity of each animal was compared with mean per-
centage inhibition of paw oedema (MPIPO) in all groups.
Group 2 (treated with piroxicam 5 mg/kg (p.o.) exhibited
highly signiﬁcant inhibition (SI) of paw oedema (P< 0.001)
andMPIPOwas found to be 84.30%, 88.33% and 90.97% after
1, 2 and 3 h, respectively. In the tested compounds (1–4) with
different doses, the groups G3, G4, G5, G7 and G8 after 1, 2
and 3 h, the groups G11, G13 and G14 after 2 and 3 h while
G6 and G10 after only 3 h exhibited highly SI of paw oedema
(P< 0.001). Different doses of 4APZ were given to the animals
of groups 3, 4, and 5 while groups 7 and 8 were treated with
4APZAB with doses 80 mg/kg and 160 mg/kg. Other groups
showed signiﬁcant or insigniﬁcant inhibition of paw oedema,
see Table 3. The details of the results are summarized in Fig. 2.
3.2.3. Effect on membrane stabilization
Membrane stabilization effect of the test compounds was
determined as described in Section 2.3.3. Piroxicam (used as
standard drug) showed signiﬁcant inhibition of haemolysis
(P< 0.05). The test compound 4APZ at dose 60 mg/kg,
4APZAB at dose 80 mg/kg, 4APZBB at dose 500 mg/kg,
4APZCB at dose 600 mg/kg and 4APZVn at dose 300 mg/kg
also showed SI of haemolysis (P< 0.05). Other test com-
pounds like 4APZ at doses 120 and 240 mg/kg, 4APZAB at
dose 160 mg/kg, and 4APZVn at dose 600 mg/kg showed
highly SI of haemolysis (P< 0.001) as shown in Table 4.
The details of the results are summarized in Fig. 3.
3.2.4. Determination of inhibition of albumin denaturation by
different doses of the compounds
Inhibition of albumin denaturation activity by the test com-
pounds was determined and results showed that piroxicam (a
standard drug) and the test compounds 4APZ (60 mg/kg),
4APZAB (160 mg/kg) and 4APZVn (150, 300 and 600 mg/
kg) showed SI of haemolysis (P< 0.05). While the test com-
pounds 4APZ at doses 120 and 240 mg/kg, 4APZBB at dose
500 mg/kg and 4APZCB at doses 150, 300 and 600 mg/kg
showed highly SI of haemolysis (P< 0.001) as shown in
Table 4. The details of the results are summarized in Fig. 4.nds on carrageenan-induced paw oedema (CIPO) in albino mice
G10 G11 G12 G13 G14 G15 G16 G17
* ** * * * – – –
** ** * * ** – – *
** ** * ** ** * * *
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Figure 1 Anti-inﬂammatory effects of compounds on carrageenan-induced paw oedema in albino mice after 1, 2 and 3 h.
Table 3 Signiﬁcance of the anti-inﬂammatory effects of the compounds on histamine-induced paw oedema (HIPO) in albino mice
after 1, 2 and 3 h.
Time Group
G2 G3 G4 G5 G6 G7 G8 G9 G10 G11 G12 G13 G14 G15 G16 G17
1 h ** ** ** ** * ** ** * * * * * * – – –
2 h ** ** ** ** * ** ** * * ** * ** ** – – *
3 h ** ** ** ** ** ** ** * ** ** * ** ** * * *
* Signiﬁcant inhibition (P< 0.05).
** Highly signiﬁcant inhibition (P< 0.001).
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Figure 2 Anti-inﬂammatory effects of compounds on histamine-induced paw oedema in albino mice after 1, 2 and 3 h.
Synthesis and biological evaluation of schiff bases of 4-aminophenazone S3653.3. Analgesic activity
3.3.1. By formalin induced paw licking method
The analgesic activity was determined by noting the time dura-
tion (in seconds) spent by animals in licking in all 17 groups.The mean time of licking for the control group was calculated
as 172.33 s. The analgesic activity for each animal in all groups
was calculated by comparing the mean percentage inhibition of
time of licking to that of the animal of the control. The group
G2 treated with piroxicam showed highly signiﬁcant inhibition
Table 4 Signiﬁcance of the effect of the compounds on membrane stabilization and inhibition of albumin denaturation.
Test Group
G2 G3 G4 G5 G6 G7 G8 G9 G 10 G 11 G 12 G 13 G 14 G 15 G 16 G 17
Hypotonicity-induced haemolysis * * ** ** – * ** – – * – – * – * **
Inhibition of albumin denaturation * * ** ** – – * – – ** ** ** ** * * *
* Signiﬁcant inhibition (P< 0.05).
** Highly signiﬁcant inhibition (P< 0.001).
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Figure 3 Inhibition of haemolysis by different doses of the compounds (mean values ± SEM).
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Figure 4 Denaturation of albumin contents by different doses of the compounds (mean values ± SEM).
S366 S. Murtaza et al.of paw licking (P< 0.001) since the mean percentage inhibi-
tion of time spent in licking was 60.32%. The groups G5,
G8, G11, G14 and G17 also showed highly signiﬁcant inhibi-
tion of paw licking (P< 0.001) Table 5. The groups treatedwith 4APZ showed highly signiﬁcant inhibition of paw licking
(P< 0.001) at dose 240 mg/kg as mean percentage inhibition
of time spent in licking at this amount was calculated to be
79.29%. The groups treated with 4APZAB, 4APZBB,
Table 5 Signiﬁcance of the analgesic effect of the compounds by formalin induced paw licking and acetic acid induced writhing in
mice.
Method Group
G2 G3 G4 G5 G6 G7 G8 G9 G10 G11 G12 G13 G14 G15 G16 G17
Formalin induced ** – * ** – * ** – * ** – * ** – * **
Acetic acid induced ** – * ** – * ** – * ** – * ** – * **
* Signiﬁcant inhibition (P< 0.05).
** Highly signiﬁcant inhibition (P< 0.001).
Synthesis and biological evaluation of schiff bases of 4-aminophenazone S3674APZCB and 4APZVn showed highly signiﬁcant inhibition of
paw licking (P< 0.001) at doses 160 mg/kg (83.48%), 500 mg/
kg (79.18%), 600 mg/kg (76.27%) and 600 mg/kg (78.18%),
respectively Fig. 5.
3.3.2. By acetic acid induced writhing test
The analgesic activity was determined by noting the number of
writhes by animals in all 17 groups. The mean number of
writhes for the control group was counted as 27.83. The
analgesic activity for each animal in all groups was calculated
by comparing the mean percentage inhibition of writhes to
control. The group G2 treated with piroxicam showed highly
signiﬁcant inhibition of paw licking (P< 0.001) since the
mean percentage inhibition of number of writhes was
63.86%. The groups G5, G8, G11, G14 and G17 also showed
highly signiﬁcant inhibition of paw licking (P< 0.001) Table 5.
The group treated with 4APZ showed highly signiﬁcant inhibi-
tion of number of writhes (P< 0.001) at dose 240 mg/kg since
the mean percentage inhibition of number of writhes was
72.22%. The groups treated with 4APZAB, 4APZBB,
4APZCB and 4APZVn showed highly signiﬁcant inhibition
of number of writhes (P< 0.001) at doses 160 mg/kg
(80.59%), 500 mg/kg (81.9%), 600 mg/kg (74.7%), and
600 mg/kg (77.15%), respectively Fig. 6.
3.4. Phenobarbitone induced sleeping time test in mice
The sleeping effect of the test compounds was determined by
inducing phenobarbitone. For all 17 groups of the animals,0
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Figure 5 Mean time of licking in mice in all groups by dithe mean time of induction and duration of sleep (in minutes)
were recorded. The onset and duration of sleep of the control
group were recorded as 27.83 min and 111.33 min, respec-
tively. In case of group G2 (treated with piroxicam) the mean
time of onset and duration of sleep were noted as 37.1 min and
83.5 min, respectively. The groups G5, G8, G11, G13, G14 and
G17 showed a highly signiﬁcant increase in duration of sleep
(P< 0.001) as well as a highly signiﬁcant decrease in mean
time of onset of sleep (P< 0.001) while G7, G10, and G12,
showed only a highly signiﬁcant decrease in mean time of onset
of sleep (P< 0.001) Table 6. The details of the result are sum-
marized in Fig. 7.
3.5. Yeast induced hyperpyrexia in rabbits after 1, 2, 3 and 4 h
The antipyretic activity of the test compounds was determined
by inducing yeast in rabbits. The mean value of temperature
before and after yeast dose was recorded in all 17 groups.
For the control group, the mean value of temperature was
noted to be 40.35 C, 40.41 C, 40.55 C, and 40.66 C after
1, 2, 3 and 4 h, respectively. In group G2 (treated with
acetylsalicylic acid) highly signiﬁcant inhibition of pyrexia
(P< 0.001) was observed after 2, 3 and 4 h. G5 (treated with
4APZ, 240 mg/kg) showed highly signiﬁcant inhibition of pyr-
exia (P< 0.001) for all tested time durations. G4 and G8
showed highly signiﬁcant results after 2 h and onwards while
G3 and G17 give highly signiﬁcant inhibition of pyrexia after
3 and 4 h. G9 and G15 exhibited insigniﬁcant results for all
time durations noted Table 7, Fig. 8.G 9 G 10 G 11 G 12 G 13 G 14 G 15 G 16 G 17
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fferent doses of the compounds (mean values ± SEM).
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Figure 6 Mean number of writhes in mice in all groups by different doses of the compounds (mean values ± SEM).
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Figure 7 Mean time of onset and duration of hypnosis in mice in all groups by different doses of the compounds (mean values ± SEM).
Table 6 Signiﬁcance of the hypnotic action of compounds in mice induced by phenobarbitone.
Group name G2 G3 G4 G5 G6 G7 G8 G9 G10 G11 G12 G13 G14 G15 G16 G17
Phenobarbitone induced hypnotic action On set * – * ** – * ** – * ** * ** ** * ** **
Duration * * * ** * ** ** * ** ** ** ** ** * – **
* Signiﬁcant decrease in time of onset and duration of hypnosis (P< 0.05).
** Highly signiﬁcant decrease in time of onset and duration of hypnosis (P< 0.001).
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Table 7 Signiﬁcance of the effect of compounds on yeast induced hyperpyrexia in rabbits after 1, 2, 3 and 4 h.
Time Group
G2 G3 G4 G5 G6 G7 G8 G9 G10 G11 G12 G13 G14 G15 G16 G17
1 h * – * ** – * * – – * – – * – – *
2 h ** * ** ** – * ** – * * – * * – – *
3 h ** ** ** ** – * ** – * * – * * – * **
4 h ** ** ** ** ** ** ** – * ** ** ** ** – * **
* Signiﬁcant inhibition of pyrexia (P< 0.05)
** Highly signiﬁcant inhibition of pyrexia (P< 0.001).
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Figure 8 Effect of compounds on yeast induced hyperpyrexia in rabbits after 1, 2, 3 and 4 h (mean values ± SEM).
Synthesis and biological evaluation of schiff bases of 4-aminophenazone S3693.6. Acute toxicity and behavioural pattern studies
Mice and rabbits treated with different doses of newly synthe-
sized compounds remained alive and they did not show any
visible sign of acute toxicity such as; restlessness, respiratory
distress, convulsion, coma or death. Even the visual behav-
ioural pattern studies in mice and rabbits revealed no promi-
nent change in the awareness, motor activity, mood, posture,
motor coordination, CNS excitation, food consumption and
body weight, such effects have already been described by
Laurence and Bacharach [25].4. Discussion
Inﬂammation, pain and fever have relation with pathophysiol-
ogy of a range of clinical conditions. Inﬂammation is the initial
response by the immune system against infection or irritation.
Many anti-inﬂammatory drugs are potential inhibitors of
cyclooxygenase (COX) pathway of arachidonic acid metabo-
lism. This produces prostaglandins which are hyperalgesic,
potent vasodilators and also contribute to erythema, oedema
and pain. Hence for treating rheumatic diseases analgesic
and anti-inﬂammatory agents have become mandatory [38].
Anti-inﬂammatory, analgesic and antipyretic actions have
similar basic mechanism, but the compounds vary in their pro-
ﬁle of activity. Modern NSAID produces serious side effects
like renal and hepatic abnormalities, metabolic disturbancesand concomitant diseases such as arterial hypertension or type
2 diabetes mellitus. Therefore, with intention, to produce
potent but safe with least side effects, four 4-aminophenazone
derivatives were synthesized and evaluated their anti-inﬂam-
matory, analgesic and antipyretic potential by the laboratory
methods. Carrageenan-induced paw oedema (CIPO) method
in mice is the most extensively used primary test for screening
of the anti-inﬂammatory activity of drugs [58] while formalin-
induced paw licking test was employed for screening of
analgesic activity. The tested compounds showed potent anti-
inﬂammatory and analgesic activities comparable to piroxicam
(standard NSAID). A dose dependent increase in anti-inﬂam-
matory activity has been observed for similar compounds
(Table 2) as suggested by Di-Rosa et al. [12]. The CIPO model
in mice has been recognized as an acute inﬂammatory model
sensitive to cyclooxygenase (COX) inhibitors. It has been
employed to estimate the primarily inhibition of the cyclooxy-
genase involved in prostaglandin (PG) synthesis by NSAID. In
oedema development period by CIPO model in mice generally
two phases have been established. The ﬁrst phase which occurs
between 0 and 2.5 h of injection of the agent is due to the
release of histamine or serotonin. The oedema volume reaches
to its maximum approximately 3 h post treatment and then
begins to decline. The second phase of inﬂammatory reaction
which is deliberate at 3 h is caused by the release of bradykinin,
protease, prostaglandin and lysosome [29]. Therefore, it can be
inferred that the inhibitory effect of the compounds on the car-
rageenan-induced inﬂammation could be due to the inhibition
S370 S. Murtaza et al.of enzyme cyclooxygenase leading to inhibition of prostaglan-
din synthesis.
Histamine-induced paw oedema (HIPO) test also revealed
the similar dose dependent results of the compounds at early
and late phases of inﬂammation (Table 3). HIPO model esti-
mated the capacity of compounds to inhibit the oedema which
is a form of chemically-induced inﬂammation wherein hista-
mine produces swelling [48]. The test compounds exhibited
peak anti-inﬂammatory activity at 2 h of the histamine chal-
lenge. The tested compounds exhibited membrane stabilization
effect by inhibiting hypotonicity-induced lysis of erythrocyte
membrane (Table 4). The erythrocyte membrane is equivalent
to lysosomal membrane [13] and its stabilization implies that
the test compounds may as well stabilize lysosomal mem-
branes. Stabilization of lysosomal membranes is signiﬁcant in
limiting the inﬂammatory response by preventing the release
of lysosomal constituents of activated neutrophil such as bac-
tericidal enzymes and proteases, which cause additional tissue
inﬂammation and damage upon extracellular release [7]. Dena-
turation of proteins is a well documented reason of inﬂamma-
tion. The tested compounds also showed inhibition of albumin
denaturation (Table 4). Extracellular proteases from plasma
transudate, inﬁltrating leukocytes, chondrocytes and synovial
cells may degrade albumin [3]. Therefore, Mizushima [27] pos-
tulated that defence against protein denaturation is the main
mechanism of action of NSAIDs before the discovery of their
inhibitory effect on cyclooxygenase [54]. The ability of the test
compounds to inhibit albumin denaturation may contribute to
its anti-inﬂammatory properties.
Formalin-induced paw licking (FIPL) test, a reliable test to
exploit the analgesic activity was used to study the analgesic
activity of the compounds. Analgesic agents are systematically
associated to the behavioural indices of pain and behavioural
indicator (licking) was used for the measurement of analgesic
consequence in this study. All the test compounds possess dose
dependent analgesic activity (Table 5) compatible as proposed
by Nawafor and Okwuasaba [31]. Formalin has been reported
to exhibit neurogenic and inﬂammatory pain [55] and it mea-
sures both centrally and peripherally mediated actions that
are characteristics of biphasic pain response. The potential
effect of test compounds observed on the ﬁrst and second
phase of formalin-induced paw licking test has suggested that
its activity may be because of its central action (Ghannadi
et al. [16]). On the contrary, the abdominal constriction
response induced by acetic acid is a sensitive process to evalu-
ate peripherally acting analgesics [15]. Analgesic effect of the
test compounds was therefore also evaluated by acetic acid-
induced writhing test. The results given in Table 5 clearly show
that all tested compounds have exhibited a dose dependent
increase in analgesic activity as also observed in FIPL method.
The method has also been related with prostanoids in general,
that is, increased level of PGE2 and PGF2a in peritoneal ﬂuids
[11], as well as lipo-oxygenase products [18]. The signiﬁcant
reduction in acetic acid-induced writhe by the test compounds
suggested their analgesic effect. It may be peripherally medi-
ated via the inhibition of synthesis and release of PGs and
other endogenous substances [22].
Phenobarbitone induced sleeping time studies showed a sig-
niﬁcant reduction in sleep latency while duration of sleeping
time was signiﬁcantly increased by the test compounds. The
compound 4APZVn showed increased duration of sleep
compared to all other test compounds (Table 6). Endogenousneurotransmitters in the brain particularly dopamine and
gamma-amino butyric acid (GABA) are implicated in themech-
anism of sleep [35,14]. Williamson et al. have described that if
liver microsomal enzymes have been damaged by disease or a
hepatotoxin, the metabolism and excretion of a barbiturate will
be impaired and therefore sleeping time will be prolonged as
compared to that of a control group [57]. Some of the test com-
pounds have prolonged PIST which indicated that the com-
pounds may not have acted via dopaminergic pathway but
perhaps by enhancing the central inhibitory effect of GABA
or by inhibiting phenobarbitone metabolism or via other mech-
anisms that may be tenuously involved in mechanism of sleep.
The test compounds also exhibited antipyretic activity
(Table 7). Infection, inﬂammation, tissue damage, graft rejec-
tion, etc. may change the set point to induce fever through
active production and maintenance of heat. Most of the anti-
pyretics inhibit cyclooxygenase-2 expression, thus inhibiting
PGE2 biosynthesis and as a consequence reduce the elevated
body temperature. Non-steroidal anti-inﬂammatory/analgesic
agents, inhibit the synthesis of prostaglandins that are
accountable for pain and pyrexia [45]. It has been recognized
that yeast induces pathogenic fever by enhancing the produc-
tion of prostaglandins, mainly PGE2, which elevates the set
point of the thermoregulatory centre in the hypothalamus
[39]. It can be suggested that test compounds may also likely
to reduce fever by reducing brain concentration of prostaglan-
din E2 especially in the hypothalamus through its action on
COX-3 [2] or by enhancement of the production of the body’s
own antipyretic substances like vasopressin and arginine [5].
5. Conclusion
Bearing in mind the above discussion, it is conceivable that all
the tested synthetic compounds have been observed to exert
steady and signiﬁcant anti-inﬂammatory analgesic and antipy-
retic activities in experimental studies. These results have also
recommended that anti-inﬂammatory action of synthetic com-
pounds is due to the attached groups or side chains. These
groups are responsible for the activity perhaps due to the inhi-
bition of release of histamine, serotonin (5-HT), kinin-like sub-
stances and prostaglandin. As compared to all other synthetic
compounds, the compound 4APZAB was found to be the most
active in all the three studies (anti-inﬂammatory, analgesic and
antipyretic activities) at lower doses. These ﬁndings, therefore,
support trials of synthetic compounds for the treatment of
rheumatism and other disorders. Though, additional studies
are essentially required to elucidate the exact mechanism(s)
of anti-inﬂammatory activities of the tested compounds to
establish their real efﬁcacy and safety in patients by following
the FDA approved protocols.
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